RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.
तुलना करने के लिए मीट्रिक्स | REPCF | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधREPCFपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.1x | −3.3x | −0.7x | |
PEG अनुपात | 0.00 | −0.02 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.5x | 4.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 94.0% | 44.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | −2.1% | 8.2% | अनलॉक करें |